NCT05456100 Chinese American Cancer Survivors Writing Study
| NCT ID | NCT05456100 |
| Status | Recruiting |
| Phase | — |
| Sponsor | New York University |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 108 participants |
| Start Date | 2022-07-14 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 108 participants in total. It began in 2022-07-14 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Chinese American Cancer Survivors Writing Study is a Randomized Controlled Trial (RCT) testing the feasibility and efficacy of the Expressive Helping (EH) intervention among Chinese American cancer survivors.
Eligibility Criteria
Inclusion Criteria: * Over 18 years old. * Prefer speaking in Mandarin Chinese or Cantonese, and able to read and write Simplified or Traditional Chinese. * Within 5 years after completing primary treatment or have completed primary treatment but still on medication for managing cancer-related symptoms. Exclusion Criteria: * Difficulties with writing * Current active participation in support groups (i.e., attending more than once per week)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05456100 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05456100 currently recruiting?
Yes, NCT05456100 is actively recruiting participants. Contact the research team at will.tsai@nyu.edu for enrollment information.
Where is the NCT05456100 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT05456100 clinical trial?
NCT05456100 is sponsored by New York University. The trial plans to enroll 108 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.